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Abstract 
Context: Literature suggests that oncogenic osteomalacia is usually caused by a benign 
mesenchymal tumor secreting fibroblast growth factor subtype-23 (FGF-23), but the 
involvement of other phosphatonins has only been scarcely reported. We have previously 
published a seemingly typical case of oncogenic osteomalacia. Following curative neoplasm 
resection, we now report unique molecular characteristics and biology of this tumor.
Case Description: A 25-year-old man had been diagnosed with severe oncogenic 
osteomalacia that gradually crippled him over 6 years. 68Ga-DOTA-TATE positron emission 
tomography/computed tomography scan localized the culprit tumor to his left sole, which 
on resection revealed a deep fibrous histiocytoma displaying a proliferation of spindle cells 
with storiform pattern associated with multinucleated giant cells resembling osteoclasts. 
Circulating FGF-23, which was elevated more than 2-fold, declined to undetectable levels 
24 h after surgery. Microarray analysis revealed increased tumor gene expression of the 
phosphatonins FGF-23, matrix extracellular phosphoglycoprotein (MEPE) and secreted 
frizzled-related protein subtype 4, with elevated levels of all 3 proteins confirmed through 
immunoblot analysis. Differential expression of genes involved in bone formation and 
bone mineralization were further identified. The patient made an astonishing recovery 
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Conclusion: This report describes oncogenic osteomalacia due to a deep fibrous 
histiocytoma, which coincidentally has been found to induce profound muscle weakness 
via the overexpression of 3 phosphatonins, which resolved fully upon radical resection 
of the tumor. Additionally, genes involved in bone formation and bone remodeling 
contribute to the molecular signature of oncogenic osteomalacia.
Key Words: phosphatonin, oncogenic osteomalacia, hypophosphatemia, FGF-23, deep fibrous histiocytoma
Oncogenic osteomalacia is a very rare endocrine 
paraneoplastic syndrome typified by chronic eucalcemic 
hypophosphatemia, phosphaturia, and normal parathy-
roid hormone (PTH) due to circulating phosphatonin se-
creted by a tumor (1). The majority of such cases are due 
to paraneoplastic secretion of fibroblast growth factor 
subtype-23 (FGF-23) by benign mesenchymal tumors, 
although malignant tumors have also been described 
(1,2). In some instances, PTH may be elevated due to 
secondary hyperparathyroidism as a compensatory re-
sponse to overcome the inhibitory effects of FGF-23 on 
1,25-dihydroxycholecalciferol.
We have previously reported the case of a young man 
who was diagnosed at age 25 with oncogenic osteomal-
acia incapacitated and wheelchair bound by the time he 
presented to us (3). The tumor in the sole of his left foot, 
which was responsible for his severe muscle weakness, was 
resected, whereupon he made an astounding recovery. This 
is a follow-up report that describes the interesting and 
unique molecular and cellular features of the tumor, which 
corroborates with the limited data in the extant literature.
Case Report
A 25-year-old Indonesian Malay man without any medical 
history developed a progressive debilitating illness 6 years 
prior to presentation at our hospital. He had seen many 
medical specialists in his home country to no avail. By the 
time he traveled by plane to seek an expert opinion from 
our medical team, he was confined to a wheelchair. At age 
19, he was still a very athletic undergraduate. He devel-
oped an excruciating arthralgia associated with proximal 
myopathy, kyphosis, and pectus excavatum. Past history 
was negative for malabsorption, muscular dystrophy, tu-
berculosis, connective tissue disease, and glucocorticoid 
use. Extensive laboratory investigations were remark-
able for a severe persistent refractory hypophosphatemia 
coupled with renal phosphate wasting associated with ele-
vated serum alkaline phosphatase and osteoporotic-range 
bone mineral density with very low Z-scores as shown 
by dual-energy X-ray absorptiometry scan (T-score −5.5, 
Z-score −5.4) suggestive of a secondary cause of bone loss. 
Serum calcium, intact PTH, and 25-hydroxyvitamin D 
levels were all normal. Bone biopsy also revealed normal 
osteocytes and lamellar arrangement without any other 
diagnostic findings. Nerve conduction tests were normal 
while electromyography displayed small amplitude poly-
phasic discharges consistent with an irritable nonspecific 
myopathy. Despite severe muscle weakness, serum cre-
atine phosphokinase, serum aldolase, and vastus lateralis 
muscle biopsy were normal. Given the negative family 
history, the late onset, normal dentition, and the biochem-
ical picture of hypophosphatemic osteomalacia, the diag-
nosis of oncogenic osteomalacia was made and a tumor 
search was performed according to a diagnostic algorithm 
reflective of the acceptable standard of care, as described 
by other groups (4,5). Notably, an initial attempt with a 
whole body 18F-FDG positron emission tomography (PET) 
scan from head to mid-thighs done in the patient’s own 
country before he consulted our hospital was negative. 
A thorough clinical examination by a senior endocrinolo-
gist (MKSL) in the team led to the discovery of a small soft 
tissue mass lesion over the sole of the left foot. This was 
ultimately proven by 68Ga-DOTA-TATE PET-computed 
tomography (CT) scan to be solely responsible for a high 
uptake “hot” spot (Fig.  1A-C). The tumor was excised 
en bloc with a good margin of normal tissue. Part of it 
was formalin fixed and paraffin embedded while the rest 
was snapped frozen. Elevated preoperative serum FGF-23 
(378 RU/mL; normal  <  180) rapidly declined to 99 RU/
mL 4 h later and became undetectable 24 h postoperatively 
(3). This was accompanied by impressive resolution of the 
hypophosphatemia and rapid recovery in muscle power. 
The patient was self-ambulant 2 months postoperatively.
On light microscopy, there was a nodular tumor 
with irregular borders lying within the subcutaneous fat 
(Fig.  2A) composed of spindle cells arranged in fascicles 
with a storiform appearance in some areas (Fig.  2B). 
A hemangiopericytoma-like appearance of the blood vessels 
with branching, staghorn blood vessels were identified, but 
a prominent vascular network was not present. A signifi-
cant population of osteoclast-like multinucleated giant cells 
was featured. Areas of hemorrhage with hemosiderin-laden 
macrophages were noted. Adipocytic component within the 
tumor, hyalinized to smudgy appearing matrix and grungy 
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The spindle cells were CD163 positive (Fig. 2C); however, 
the multinucleated giant cells were negative for this marker. 
The stains for STAT6, CD34, CD31, ERG, SMA, desmin, 
and S-100 were negative and excluded differential diag-
noses, such as vasoformative tumor (eg, hemangioma), 
dermatofibrosarcoma protruberans, solitary fibrous tumor, 
and smooth muscle tumor. Factor XIIIa staining was con-
fined to the multinucleated giant cells (Fig. 2D). Based on 
these findings of CD163 and factor XIIIa expressions, fi-
brous histiocytoma was favored as it corroborated with the 
morphological findings. Thus, the histological diagnosis 
was judged to be more consistent with a deep benign fi-
brous histiocytoma than the usual mesenchymal tumor typ-
ically seen in oncogenic osteomalacia.
To better characterize the tumor ex vivo, molecular 
analyses were undertaken. Microarray analysis was per-
formed to compare gene expression differences between 
tumor, adjacent normal tissue (labeled “adjacent”) and 
resected overlying skin (labeled “skin”). Analysis revealed 
687 significantly upregulated genes in tumor vs adjacent 
and 1837 genes in tumor vs skin, with 290 common genes 
upregulated between the 2. Similarly, there were 623 sig-
nificantly downregulated genes in tumor vs adjacent and 
1522 genes in tumor vs skin, with 110 common genes 
downregulated between the 2.  Overall, there were 400 
common genes in the combined up- and downregulated 
list, which were used for pathway analysis. The complete 
raw data pertaining to this microarray analysis can be 
found at the Gene Expression Omnibus data repository 
(accession no. GSE160445) (6). Subsequent pathway ana-
lysis revealed that processes, such as cell proliferation and 
differentiation, cell adhesion/migration, and epithelial-to-
mesenchymal transition were significantly represented. In 
particular, Hedgehog and PTH signaling pathways in bone 
and cartilage development were significantly positively en-
riched (P-value = 4.084 × 10–4 with a false discovery rate 
(FDR) of 0.02275) (Table 1), which is highly relevant in 
the context of a soft tissue tumor that influences muscle 
and bone.
Importantly, microarray analysis revealed that the ex-
pression of phosphatonins, previously linked to oncogenic 
osteomalacia (7), were significantly upregulated in tumor 
tissue, when compared to adjacent tissue, with an ~360-
fold increase in FGF-23, ~206-fold increase in matrix 
extracellular phosphoglycoprotein (MEPE), and an ~150-
fold increase in secreted frizzled-related protein subtype 
4 (sFRP-4) gene expression noted (Table 2). A significant 
increase in the expression of FGF-23 (~3700-fold) and 
sFRP-4 (~3400-fold) was also noted in tumor tissue, when 
compared to skin tissue (Table 2) and although not signifi-
cant (FDR P = 0.053), the expression of MEPE was also 
upregulated (~8300-fold) in tumor tissue, when compared 
to skin tissue (Table 2). Subsequent immunoblot analyses 
confirmed increased levels of the phosphatonins FGF-23, 
MEPE, and sFRP-4 (Fig. 3) in tumor tissue, when compared 
to adjacent tissue. Microarray analysis further revealed 
increased expression of DMP1 (a gene that encodes for 
dentin matrix protein-1, which is implicated in regulating 
bone mineralization (8), in tumor tissue, when compared 
to adjacent tissue (~30-fold) and skin tissue (~45-fold), al-
though the increased expression was not significant (FDR 
P = 0.12 and P = 0.131 in tumor tissue vs adjacent and skin 
tissue, respectively) (Table 2). However, in contrast to the 
microarray data, immunoblot analysis revealed a reduction 
in dentin matrix protein-1 levels in tumor tissue (Fig. 3).
Interestingly, microarray analysis further revealed sig-
nificantly increased expression of genes associated with 
osteopenia (Gremlin1; GREM-1) (9), bone mineraliza-
tion and osteoblast differentiation (secreted phosphopro-
tein 1; SPP1 [osteopontin; OPN] and tenascin C; TNC) 
(10, 11) and significantly reduced expression of a gene 
involved in bone formation (FosB proto-oncogene, AP-1 
transcription factor subunit; FOSB) (12), in tumor tissue, 
when compared to both adjacent and skin tissue (Table 2). 
Subsequent quantitative polymerase chain reaction (qPCR) 
analysis was performed to confirm GREM1 (3 transcript 
variants), SPP1 (2 transcript variants), TNC (1 transcript 




Figure 1. Sagittal section images of the sole of the left foot. Image 
reveals a lesion (arrowhead) on CT (A) corresponding to a region of 
intense 68Ga-DOTATATE radionuclide uptake on PET scan (B), both of 











niversity user on 04 February 2021
4  The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. XX, No. XX
changes across the tissue samples. Quantitative PCR data 
were normalized to both GAPDH (Fig.  4A) and HPRT 
(Fig. 4B), with comparable gene expression changes noted. 
In contrast to microarray results, the expression of GREM-
1 was reduced in tumor tissue samples, when compared 
to adjacent stroma tissue (Fig. 4A and B). However, con-
sistent with microarray data, increased expression of SPP1 
and TNC and reduced expression of FOSB was confirmed 
in tumor tissue, when compared to adjacent and skin tis-
sues (Fig. 4A and B).
Table 1. Significantly enriched pathways in tumor tissue
No Pathway P-value FDR P-value
1 Cell adhesion_ECM remodeling 2.76–07 0.0001247
2 Cell adhesion_Chemokines and adhesion 1.06–05 0.0024
3 Immune response_Antigen presentation by MHC class II 4.31–05 0.006169
4 Cell adhesion_Endothelial cell contacts by non-junctional mechanisms 5.47-05 0.006169
5 Cell adhesion_Integrin-mediated cell adhesion and migration 1.93–04 0.01743
6 LRRK2 in neurons in Parkinson’s disease 2.68–04 0.02018
7 Cell adhesion_Plasmin signaling 3.57–04 0.02275
8 Development_Hedgehog and PTH signaling pathways in bone and cartilage development 4.08-04 0.02275
9 Cytoskeleton remodeling_Cytoskeleton remodeling 4.54-04 0.02275
10 Transport_Macropinocytosis regulation by growth factors 8.59-04 0.03225
11 Development_Leptin signaling via JAK/STAT and MAPK cascades 9.20-04 0.03225
12 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 9.34-04 0.03225
13 Cell adhesion_Cadherin-mediated cell adhesion 1.07–03 0.03225
14 Immune response_IL-10 signaling pathway 1.07–03 0.03225
15 Development_S1P2 and S1P3 receptors in cell proliferation and differentiation 1.07–03 0.03225
16 Regulation of degradation of deltaF508 CFTR in CF 1.24–03 0.035
17 Development_Slit-Robo signaling 1.86–03 0.04935
Table shows significantly enriched pathways (FDR P-value  <  0.05) in tumor tissue based on identified differentially expressed genes. Common up- and 
downregulated genes were identified upon comparing tumor tissue to both adjacent and skin tissue. Pathway names, raw P-value, and FDR P-value are given.
A B
DC
Figure 2. Images of histology and immunohistochemistry staining of tumour tissue. (A) Low power view revealing a partially circumscribed tumor 
with occasional irregular borders lying within the subcutaneous fat of the skin. Note the presence of blood vessels with staghorn appearance (indi-
cated by arrow) and hemosiderin deposition. (H&E, magnification ×20). (B) Medium power view disclosing a proliferation of slender to plump spindle 
cells in fascicles with storiform arrangement (indicated by arrow) in some areas in association with osteoclast like multinucleated giant cells. (hema-
toxylin and eosin, original magnification ×100). (C) Decoration of spindle cells by antibody against CD163 on high power view. Note that the lack of 
pick up in the multinucleated giant cells (Ventana Optiview, original magnification ×600). (D) Factor XIIIa staining highlighting the multinucleated 
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Institutional Review Board Approval
Ethical approval for the conduct of this research on the bio-
banked tissue samples of this patient was formally obtained 
from the Institutional Review Board of the National 
Healthcare Group (NHG) of Singapore. The ethics code is 
C/2013/00206. This study was done in accordance with the 
principles set out in the Declaration of Helsinki.
Materials and Methods
68Ga-DOTA-TATE PET-CT fusion scan
Peptide labeling with 68Ga in the Department of Nuclear 
Medicine and Molecular Imaging, Singapore General 
Hospital was performed manually. In brief, 250  µg 
HA-DOTA-[Tyr3] octreotate precursor was radiolabeled 
with gallium-68 eluted from 68Ge/68Ga generator 
(iThemba, South Africa). The 68Ge/68Ga generator was 
eluted with 10 mL of 0.6 N hydrochloric acid. Two milli-
liters of the 68Ga eluent was collected into a vented pre-
heated vial. Two milliliters of Hepes buffer (280 mg/mL) 
was added, followed by 250 µg of HA-dotatate. The vial 
was heated for 15 min at 100°C. One milliliter of Hepes 
buffer (1060 mg/ml) and 0.8 mL of 2 N NaOH were then 
added. The final product was filtered through a 0.22 µm 
Millex filter. Radiochemical purity was established by 
thin layer chromatography and the purity exceeded 90%. 
Whole-body 68Ga HA-DOTATATE PET/CT imaging was 
performed using a dedicated General Electric PET/CT 
system (GE Discovery 690 VCT, GE Medical Systems, 
Table 2. Selected subset of differentially expressed genes
Tumor Tissue vs Adjacent Tissue Tumor Tissue vs Skin Tissue
Symbol Fold change P-value FDR P-value Fold change P-value FDR P-value
FGF23 361.36 0.0012 0.0425 3726.29 0.0001 0.0104
MEPE 205.88 0.0005 0.0326 8308.04 0.0055 0.053
SFRP4 155.13 0.0007 0.0354 3453.5 0.0003 0.0145
DMP1 31.13 0.0151 0.12 44.46 0.0312 0.131
GREM1 57.8 0.0009 0.0387 10.1 0.0047 0.0493
SPP1 141.81 4.75–05 0.0147 4805.01 0.003 0.0403
TNC 90.5 9.13-05 0.0191 215.67 0.0003 0.0149
FOSB −37.43 0.0004 0.0305 −368.83 7.87-06 0.0033
Table lists a selected subset of differentially expressed genes, identified through microarray analysis comparing (i) tumor tissue and adjacent tissue and (ii) tumor 
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Figure 3. Immunoblot analysis. (A) Fibroblast growth factor subtype 23 (FGF-23), (B) matrix extracellular phosphoglycoprotein (MEPE), (C) secreted 
frizzled-related protein subtype 4 (sFRP4) and (D) Dentin matrix protein 1 (DMP1) protein levels within tumor tissue (tumor) and adjacent normal 
tissue (control). Ponceau S staining was performed as a loading control. The size (in KDa) of relevant molecular weight marker proteins are indicated 
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LLC, Waukesha, WI, USA). The scan was acquired from 
the skull vertex to feet. Computed tomography was per-
formed without intravenous contrast media application 
for the purpose of attenuation correction as follows: 
100 kV; “GE smart mA dose modulation” helical thick-
ness, 3.75  mm; table speed, 0.984  mm; rotation time, 
0.8 s. Attenuation-corrected whole-body (vertex of skull 
to feet) scan was acquired in 3-dimensional mode (2-min 
emission time per bed position). Depending on body 
length, 16 bed positions were used with a field of view of 
70 cm. For iterative reconstruction of the time of flight 
data, 3 iterations and 24 subsets with a filter cutoff of 7.0 
were used. The patient received an intravenous injection 
of 203 MBq of 68Ga HA-DOTATATE and the acquisition 
was started after an uptake time of 60 min. Multiplanar 
reconstruction was performed for image interpretation. 
Images were interpreted by an experienced nuclear medi-
cine physician. A semiquantitative measurement of inten-
sity of tracer uptake was performed using the maximum 
standardized uptake value. For maximum standardized 
uptake value calculations, volumes of interest of the le-
sion was drawn automatically and adjusted manually 
to lesion size, applying a commercially available soft-
ware provided by the vendor of the PET/CT-scanner (GE 
AWS).
Histology and immunohistochemistry staining
The excision specimen from the left foot comprising skin 
and subcutaneous tissue was received in buffered neu-
tral formalin. The tumor in the specimen was extensively 
sampled and processed for routine hematoxylin and 
eosin–stained sections. Five-μm sections from formalin-
fixed, paraffin-embedded tissues were stained with anti-
bodies against CD31 (Neomarker), CD34 (DAKO), ERG 
(Cell Marque), STAT6 (Cell Marque), Factor XIIIa (Cell 
Marque), CD163 (Cell Marque), desmin (DAKO), and 
SMA (DAKO) using the Ventana Optiview detection kit 
on the Roche Ventana BenchMark ULTRA slide stainer 
(Roche Diagnostics) after antigen retrieval, if required. For 
CD34, STAT6, Factor XIIIa, CD163, and desmin stains, the 
ULTRA cell conditioning method on the Roche Ventana 
BenchMark ULTRA slide stainer was used for antigen re-
trieval. For ERG and CD31 stains, the pressure cooker with 
citrate buffer at pH6 method was employed. For SMA, no 
antigen retrieval treatment was required.
Ribonucleic acid isolation
Tumor tissue, adjacent normal tissue and resected overlying 
skin tissue biopsies were stored in RNAlater (Ambion) 
prior to ribonucleic acid (RNA) extraction. Total RNA 
was isolated from each tissue using QIAzol lysis reagent 
(Qiagen), as per the manufacturer’s instructions. The integ-
rity of isolated RNA was evaluated using the Agilent 2100 
Bioanalyzer system and the RNA 6000 Nano Kit (Agilent). 
All samples were stored at −80°C prior to further use.
Microarray and pathway analysis
Purified RNA was subjected to microarray analysis using 
the Illumina human HT-12 beadchip and in-house hy-
bridization, quantification and analysis protocols (OCI 
Genomics Centre, Toronto, Canada). Microarray raw data 
were submitted to Gene Expression Omnibus (Accession 
No. GSE160445) (6). From the microarray data, 2 com-
parisons were made—tumor vs adjacent tissue and tumor vs 
skin. A 1-way analysis of variance and Benjamini-Hochberg 
multiple testing correction procedure were used to identify 
statistically significant changes in gene expression (defined 
as adjusted P-value < 0.05) using the software ArrayStudio 
(version 6.0) from Omicsoft. MetaCore (version 6.8, build 
































































































































Figure 4. Graphs displaying qPCR analysis of three transcript variants 
of GREM1 (Var1, Var2, and Var3), two transcript variants of SPP1 (All and 
Var1), TNC and 2 transcript variants of FOSB (Var1 and Var2) in tumor 
tissue (Tumor), adjacent normal tissue (Adjacent) and resected over-
lying skin (Skin). Data are shown as fold change, relative to adjacent 
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enriched pathways based on the differentially expressed 
genes. For this purpose, the common up and down genes 
(significant at FDR P-value < 0.05) were identified from the 
2 comparisons mentioned earlier. To calculate the FDR, we 
have used the method by Benjamini and Hochberg, as is 
standard in gene expression analysis studies (13).
Reverse transcription and quantitative PCR
A total of 0.250  μg of RNA was subjected to reverse 
transcription using the iScript complementary deoxy-
ribonucleic acid (DNA) synthesis kit (Bio Rad Cat No: 
170–8891), as per the manufacturer’s protocol. Prior to 
qPCR analysis complementary DNA was diluted 1:10 in 
autoclaved MilliQ water. Quantitative PCR analysis was 
performed with 3 technical replicates using the SsoFast 
EvaGreen Supermix (Bio-Rad cat no: 7500001227)  and 
the Bio-Rad CFX96 real-time polymerase chain reaction 
detection system. The qPCR conditions used were as fol-
lows: 95°C for 3 min, followed by 40 cycles of a 3-step 
reaction: 95°C for 10 s, 60°C for 30 s, and 72°C for 30 s. 
These cycles were followed by a melt curve protocol: 95°C 
for 10 s, followed by 65°C to 95°C in 10 s increments of 
0.5°C. Gene expression fold change was calculated using 
the 2-ΔΔCt method, with values normalized to GAPDH and 
HPRT. The sequences of the primers used in this study are 
GREM1 (Var1)-F: 5’-ACT GAC AGT ATG AGC CGC 
AC-3’, GREM1 (Var1)-R: 5’-GCA CCT TGG GAC CCT 
TTC TT-3’; GREM1 (Var2)-F: 5’-AGA CAA GGC CCT 
GCA TGT G-3’, GREM1 (Var2)-R: 5’-GAA GCG GTT 
GAT GGT GC-3’; GREM1 (Var3)-F: 5’-CGC GTC ACT 
CTC GGT CC-3’, GREM1 (Var3)-R: 5’- CAC ATG CAG 
GGC TCC CAC-3’; SPP1 (Var1)-F: 5’-GGC ATC ACC 
TGT GCC ATA C-3’, SPP1 (Var1)-R: 5’-CTT GGA AGG 
GTC TGT GGG G-3’; SPP1 (All)-F: 5’-TGT TGG AGG 
ATG TCT GC-3’, SPP1 (All)-R: 5’-AGT TTT CCT TGG 
TCG GCG TT-3’; TNC-F: 5’-CGG TGG ATT CTG GGA 
AG-3’, TNC-R: 5’-TCC GGT TCG GCT TCT GTA AC-3’; 
FOSB (Var1)-F: 5’-GAG CTG ACC GAC CGA CTC-
3’, FOSB (Var1)-R: 5’-CAA ATC TCT CAC CTC CGC 
CA-3’; FOSB (Var2)-F: 5’-CGG TGG ATT CTG GGA 
AG-3’, FOSB (Var2)-R: 5’-TCT GTC TCC GTC TCC TCT 
CG-3’; GAPDH-F: 5’-CGC TCT CTG CTC CTG TT-3’, 
GAPDH-R: 5’-CCA TGG TGT CTG AGC GAT GT-3’; 
HPRT-F: 5’-TGA GGA TTT GGA AAG GGT GTT-3’, and 
HPRT-R: 5’-ATG TAA TCC AGC AGG TCA GCA-3’.
Protein extraction and immunoblot analysis
Total protein was extracted from tumor tissue and control 
(adjacent normal tissue) using radioimmunoprecipitation 
assay buffer containing: 50 mM Tris HCl pH7.5, 150 mM 
NaCl, 1.0  mM ethylenediamine tetra-acetate pH 8.0, 
1.0% NP-40, 0.1% sodium dodecylsulphate, 0.5% so-
dium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 
25 mM sodium fluoride, 1 mM sodium orthovanadate, 1× 
complete protease inhibitor cocktail (Roche Diagnostics) 
in phosphate-buffered saline. Bradford reagent (Bio-Rad) 
was used to quantify protein samples. For immunoblot-
ting, 20 µg of total protein was separated on 4% to 12% 
NuPAGE Bis-Tris protein gels (Invitrogen), followed by 
transfer to nitrocellulose membrane using the Xcell Blot 
Module (Invitrogen). The primary antibodies used in this 
report were human anti-dentin matrix protein-1 (1:200, 
Santa Cruz, no. sc-73633), anti-MEPE (1:400, Santa 
Cruz, no. sc-377035), anti-FGF-23 (1:400, Abcam, no. 
ab56326), anti-sFRP4 (1:1000, Abcam, no. ab154167). 
Secondary HRP-conjugated antibodies used in this report 
were antigoat (1:5000, Bio-Rad, no. 1721034), antirabbit 
(1:5000, Bio-Rad, no.  1706515)  and antimouse (1:5000, 
Bio-Rad, no. 1706516). Protein bands were detected using 
Western Lightning Plus Chemiluminescent reagent (Perkin 
Elmer Life Sciences) and the ChemiDoc Imaging System 
(Bio-Rad). Ponceau S staining was conducted as a loading 
control.
Discussion
Oncogenic osteomalacia is a very rare paraneoplastic 
endocrinopathy with metabolic bone sequelae usually 
caused by benign mesenchymal tumors. In the literature, 
malignant tumors such as osteosarcoma and giant cell tu-
mors have also been found to overexpress FGF-23 and re-
sulted in oncogenic osteomalacia (1). However, our patient’s 
paraneoplastic phosphatonin-mediated hypophosphatemia 
due to a deep fibrous histiocytoma is much rarer by com-
parison to benign mesenchymal tumors (14); an exten-
sive search only yielded a similar case reported nearly a 
decade ago (15). Notably, we have also demonstrated 
in our case of oncogenic osteomalacia not only elevated 
tumor production of FGF-23, but also simultaneous tumor 
co-expression of the additional phosphatonins MEPE and 
sFRP4. Only 1 other group had previously published the 
involvement of these phosphatonins in oncogenic osteo-
malacia nearly 2 decades ago and defined their role in the 
biology of bone and mineral metabolism (16). It is likely 
that these 3 phosphatonins jointly exert synergistic phos-
phate wasting actions and intensify the degree of muscle 
weakness and deterioration of bone micro-architecture. 
In agreement with De Beur et al (16), we found increased 
tumor expression of DMP1 messenger RNA via microarray 
analysis in our case of oncogenic osteomalacia. To our 
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levels of DMP1 in tumor tissue relative to control adjacent 
tissue. Importantly, these data are consistent with previous 
work that suggests a role for reduced DMP1 in stimulating 
increased expression of FGF-23, hypophosphatemia, and 
osteomalacia (8,17), which is quite consistent with the in-
creased FGF-23 and phenotype observed in this patient. It 
is interesting to surmise that the inverse relationship be-
tween DMP1 messenger RNA and DMP1 protein levels 
noted in this study may be due to post-transcriptional 
regulation processes or perhaps altered protein stability. 
However, further work will need to be undertaken to study 
DMP1 gene/protein regulation in more detail in cases of 
oncogenic osteomalacia to determine this.
Because a normal serum phosphate is necessary for cal-
cium phosphate homeostasis in bones for skeletal health, 
chronic severe hypophosphatemia can cause osteomal-
acia. Fortuitously, based on the microarray analysis data, 
we found GREM1, SPP1, and TNC genes to be signifi-
cantly upregulated while the FOSB was significantly 
downregulated. GREM1 (Gremlin-1) encodes for a se-
creted glycoprotein that antagonizes the function of bone 
morphogenetic proteins. Overexpression of Gremlin has 
been reported to lead to osteopenia (9); thus, it is interesting 
to surmise that elevated GREM1 may contribute to the 
bone loss and osteomalacia phenotype observed in this 
individual. However, it is important to highlight that the 
increased GREM1 expression identified by microarray 
analysis was not validated by subsequent qPCR and in 
fact, GREM1 expression was conversely found to be ele-
vated in adjacent normal tissue, when compared to tumor 
tissue by qPCR (Fig.  4). Although microarray is a valid 
approach to assess gene expression it is important to note 
that due to the intrinsic variability present in microarray 
data there is a potential for identification of false positives 
(18). This may explain the disparity in GREM1 expression 
noted in the present study and further emphasizes the im-
portance of validating microarray data using additional 
methodology such as qPCR. SPP1 (secreted phosphopro-
tein 1), otherwise called osteopontin, is a small integrin-
binding ligand, N-linked glycoprotein that constitutes part 
of the extracellular matrix of bones and dentin (19). SPP1 
has been shown to exhibit strong mineral binding prop-
erties and function to inhibit bone mineralization (10,20). 
Additionally, SPP1 is required for stimulating osteoclast-
mediated bone resorption and as such has important roles 
in regulating osteoclast activity during bone remodeling 
(21,22). Overexpression of SPP1 has also been reported to 
inhibit bone mineralization in FGF-23–deficient mice and 
is suggested to contribute to the osteomalacia observed 
in these mice (23). Hence, the severe loss of bone mass 
encountered in this case is unlikely to be due to chronic 
hypophosphatemia alone. We postulate that SPP1 plays a 
role in contributing to the gross osteomalacia in this form 
of paraneoplastic metabolic bone disorder. If SPP1 is sub-
sequently substantiated by others in future, it would con-
stitute a novel pathway in the pathobiology of oncogenic 
osteomalacia. Tenascin-C, the protein product of the TNC 
gene, is a matricellular protein whose physiological func-
tion includes embryonic development, cell adhesion, cell 
migration, wound healing, and osteoblastic proliferation 
and differentiation (11,24). Notably, tenascin-C also plays 
a role in tissue injury, inflammation, pathological tissue 
remodeling and cancer invasion (25). It remains intriguing 
whether tenascin-C expression by this tumor contributed 
to patient disease manifestation or acted as a survival 
factor for the tumor itself. One plausible way to delin-
eate the role of tenascin C in tumor survival as opposed to 
inducing oncogenic osteomalacia is to study its relative ex-
pression in similar tumors (ie, deep fibrous histiocytomas), 
which lack any clinical association with osteomalacia. The 
other remarkable finding is the significant downregulation 
of the FOSB gene, one that deserves some comment and 
perhaps further research. FOSB is a protein encoded by 
the FBJ murine osteosarcoma viral oncogene homolog B 
gene. FOSB heterodimerizes with DNA-binding proteins, 
including the Jun-related family of proteins (c-Jun, JunB, 
and JunD) to form the dimeric transcription factor AP-1, 
which has a critical role in regulating downstream gene ex-
pression in response to numerous stimuli (26). In terms of 
bone physiology, there is evidence to suggest that ΔFOSB, 
a naturally occurring truncated variant of FOSB formed 
through alternative splicing of the FOSB gene (12), has 
important functions in bone formation. Specifically, it has 
been shown that overexpression of ΔFOSB leads to signifi-
cantly increased bone formation in mice (12). Thus, it is 
interesting to surmise that reduced expression of FOSB, as 
noted in this case, may be a factor contributing to osteo-
malacia; however, further work will need to be performed 
to confirm this. Nevertheless, we acknowledge that we have 
not measured the levels of these proteins in the circulation, 
and hence the previously discussed endocrine effects medi-
ated by SPP1, TNC, and FOSB in disordered bone turnover 
in this patient remains speculative at best.
The fact that muscle power was rapidly restored fol-
lowing successful surgical resection of the tumor implied 
that the myologic changes are, at least in part, relatively 
reversible. Unlike established severe primary osteoporosis, 
which typically requires a much longer duration of sev-
eral years before any significant reversal in bone mass and 
quality following appropriate therapeutic intervention, the 
rate of recovery in bone density upon eradication of the 
underlying cause in secondary osteoporosis is much more 
rapid (27,28). Despite very severely reduced bone density, 
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dual-energy X-ray absorptiometry performed 11  months 
later showing dramatic improvement in bone density to a 
T-score of −1.8.
In summary, the strengths of our report include an 
in-depth analysis of the gene expression profile of a cul-
prit oncogenic osteomalacia-inducing tumor by micro-
array technique along with simultaneous immunoblot 
evidence of protein expression; we also highlight the 
plausible role of newer factors like SPP1, TNC, and FosB 
for the first time and elaborated on the pathway ana-
lysis. We acknowledge some weaknesses, one of which 
is the unavailability of a similar tumor tissue without 
osteomalacia as a control, which could then provide 
more insightful analysis and interpretation for the dif-
ferentially expressed genes beyond what we can surmise 
by comparison against adjacent nontumoral tissue. Also, 
while we have found upregulation of SPP1 and TNC and 
downregulation of FOSB in the tumor, we have not as-
sayed the plasma for these proteins. Thus, we have not 
confirmed that such proteins are circulating and exert 
endocrine actions on the skeleton per se. However, given 
that these proteins play a role in the molecular pathways 
of bone turnover, it would be important for more re-
search to be done to ascertain their role in bone biology 
and the pathogenesis of oncogenic osteomalacia.
Finally, a note should be emphasized about how 
standard-field 18F-FDG-PET imaging can totally miss the 
culprit tumors causing oncogenic osteomalacia (29,30). 
Our case illustrates this pitfall very elegantly and reiter-
ates the need for clinicians to be especially thorough in 
the physical examination of patients being worked up for 
muscle weakness associated with skeletal disorders and for 
nuclear physicians to ensure that the PET imaging field ac-
tually covers the whole body in those suspected to suffer 
from this rare disorder.
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